gemcitabine has been researched along with Experimental Mammary Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, Q; Huang, M; Li, L; Li, M; Liu, R; Sun, J; Wu, L; Zhang, S; Zhang, W | 1 |
| Banáth, JP; Bennewith, KL; Bosiljcic, M; Cederberg, RA; Collier, JL; Franks, SE; Halvorsen, EC; Hamer, M; Hamilton, MJ; Harbourne, BT; Kim, AY; LePard, NE; Rossi, FM; Shi, R | 1 |
| Chen, L; Hu, C; Li, G; Liang, Z; Wang, Y; Yu, T; Zhuang, W | 1 |
| Chen, L; Hu, C; Li, G; Liang, Z; Su, X; Wang, Y; Yu, T; Zhuang, W | 1 |
| Dong, S; Duan, Y; Guo, Y; Li, Z; Ma, M; Niu, L; Shi, Y; Wang, C; Wang, N; Zhang, M | 1 |
| Balasubramanian, SU; Harfouche, R; Luchette, M; Papa, AL; Sarangi, S; Sengupta, S; Sidiqui, A | 1 |
| Agrawal, AK; Das, M; Jain, R; Jain, S; Thanki, K | 1 |
| Balzarini, J; Fieuws, S; Hofer, A; Liekens, S; Noppen, S; Ranjbarian, F; Sabuncuoğlu, S; Vande Voorde, J | 1 |
| Bally, MB; Corcoran, JA; Franco, OL; Hancock, REW; Haney, EF; Hilchie, AL; Hoskin, DW; Sharon, AJ | 1 |
| Leung, J; St-Onge, P; Stagg, J; Suh, WK | 1 |
| Alli, E; Ford, JM; Hartman, AR; Lin, PS; McPherson, L; Sharma, VB | 1 |
| Blando, JM; Cui, Z; De Angel, RE; Dunlap, SM; Hogan, MG; Hursting, SD; Lansakara-P, DS; Sandoval, MA | 1 |
| Chen, WR; Ishmael, DR; Liu, H; Nordquist, JA; Nordquist, RE | 1 |
| Kiselyov, A | 1 |
| Altavista, P; Ceciarelli, F; Cividalli, A; Cruciani, G; Livdi, E; Mauro, F; Tirindelli Danesi, D | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Grindey, GB; Rockwell, S | 1 |
17 other study(ies) available for gemcitabine and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Design, synthesis and bioevaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazoles as tubulin polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Structure; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2021 |
Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Topics: Animals; Antigens, Ly; Antineoplastic Agents; CD11b Antigen; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Eosinophils; Female; Gemcitabine; Killer Cells, Natural; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mastectomy; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells | 2019 |
Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Particle Size; Photochemotherapy; Photosensitizing Agents; Polymers; Porphyrins; Prodrugs; Surface Properties | 2020 |
pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Combined Modality Therapy; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Hydrogen-Ion Concentration; Lasers; Mammary Neoplasms, Experimental; Mice; Micelles; Molecular Structure; Optical Imaging; Particle Size; Photochemotherapy; Photosensitizing Agents; Polymers; Porphyrins; Prodrugs; Singlet Oxygen; Surface Properties | 2020 |
Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Surface Properties | 2018 |
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyethylene Glycols; Time Factors; Treatment Outcome; Tumor Burden | 2013 |
Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Kidney; Liver; Macromolecular Substances; Mammary Neoplasms, Experimental; MCF-7 Cells; Methotrexate; Mice; Molecular Structure; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Risk Factors; Structure-Activity Relationship | 2014 |
Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mice; Mycoplasma hyorhinis; Mycoplasma Infections; Pyrimidine Phosphorylases; Tetrahydrouridine; Thymidine; Tumor Microenvironment | 2014 |
Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Circular Dichroism; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Peptides; Wasp Venoms | 2016 |
Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Tumor Burden; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2017 |
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Topics: Animals; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Damage; DNA Repair; Epithelial Cells; Female; Gemcitabine; Genes, BRCA1; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice | 2011 |
Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Obesity; Postmenopause; Random Allocation | 2013 |
Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mitoguazone; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Paclitaxel; Statistics, Nonparametric | 2000 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Tumor Cells, Cultured; X-Rays | 1992 |